Modified immune cells and uses thereof
Patent Information
- Application Number
- JP2023525626
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-10-26
- Filing Date
- 2021-10-26
- Publication Date
- 2024-11-05
AI Technical Summary
The challenge lies in rapidly obtaining a population of T cells from patients that can specifically identify harmful cells, such as cancer cells or viral host cells, and modifying these cells to enhance their efficiency and safety for cell therapy, considering the heterogeneity of tumors, individual MHC, and randomness of T cell receptor generation.
The method involves isolating PD-1 positive T cells from peripheral blood mononuclear cells, modifying them by reducing or eliminating PD-1 expression through genetic techniques like CRISPR/Cas, and enhancing them with potentiating receptors and chimeric antigen receptors (CARs) to improve their immune activity and targeting capabilities.
The modified T cells demonstrate enhanced discrimination and immune activity against target cells, effectively reducing tumor growth and viral infections, with improved safety profiles and reduced immunosuppressive effects.
Abstract
Description
[Technical Field]
[0001] The present invention belongs to the field of biomedicine technology, specifically to the field of immune cell therapy. [Background technology]
[0002] T cells are one of the most important specific immune cells in the human body and have recently been playing an important role in the field of cell therapy, which has been gaining attention. For example, cell therapy can be performed by modifying a patient's autologous T cells and infusing them into the patient. However, given the heterogeneity of tumors, the individuality of patient MHC phenotypes, and the random nature of T cell receptor (TCR) biogenesis (VDJ rearrangement), the T cell populations that specifically recognize harmful cells in the patient's body are diverse; in other words, T cell populations containing highly individualized TCR cohorts. How to rapidly obtain T cell populations from the patient's own body that can specifically recognize harmful cells (cancer cells or viral host cells), modify them based on these, and then apply them to cell therapy more efficiently and safely remains a technical challenge. Summary of the Invention
[0003] The inventors of the present invention have demonstrated that PD-1 positive T cells (PD-1 + They believe that PD-1 (T cells) is a group of cells in a suppressed state, and that these cells are likely T cells that can recognize target cells and have interacted with PD-L1 on the target cells. + T cells can be considered as a population of T cells that attack harmful cells. Indeed, since the T cells in this population have already come into contact with harmful cells, these T cells are thought to have the ability to target harmful cells. PD-1 in the treated peripheral blood + T cells hold promise for the treatment of various diseases, particularly tumors and infectious diseases. +The advantage of T cells is that they have relatively good discrimination properties against harmful cells, but the disadvantage is that high expression of PD-1 causes these cells to become exhausted, suppressing their function and making it difficult for them to exert their killing effect. + In order to provide T cells with both distinguishing properties and immune activity, the present invention uses PD-1 + The present invention is accomplished by considering several modification methods that overcome the suppressive state of T cells.
[0004] Thus, in a first aspect, the present application relates to modified immune cells, said immune cells being PD-1 positive T (PD-1 + Preferably, the PD-1 + The T cells are derived from peripheral blood mononuclear cells (PBMCs). For example, the PD-1 + T cells are cells obtained by sorting PBMCs, for example, by using PD-1 and CD3 as markers.
[0005] In a preferred embodiment, the modification is PD-1 + The modification can reduce or eliminate the suppressive state of T cells, for example, by genetic modification and / or protein modification of the immune cells.
[0006] In one specific embodiment, the modification is + PD1, such that PD-1 expression on T cells is absent or reduced + The genetic modification is performed on T cells. The genetic modification can be performed in vivo or in vitro. In one embodiment, the genetic modification is performed in vivo by gene editing or gene therapy. In another embodiment, the genetic modification is performed in vitro, for example, by cloning the PD-1 + The genetic modification is carried out during the preparation of T cells. +The method can be to knock out or knock down endogenous PD-1 in T cells. Means for knocking out endogenous PD-1 genes include, but are not limited to, CRISPR / Cas methods, TALEN, etc.
[0007] In one specific embodiment, the modification is + PD-1 was modified to reduce the binding ability of PD-1 on the surface of T cells to its ligands compared to before modification. + In a specific embodiment, the PD-1 antibody modifies PD-1 on the surface of T cells. + The PD-1 antibody is coupled to the PD-1 so as to competitively bind to the PD-1 on the surface of the T cell. + Modification is achieved by combining PD-1 with T cells to reduce its ability to bind to its ligand. In one embodiment, the modification is achieved in vivo by co-administration with a PD-1 antibody. In another embodiment, the modification is achieved in vitro, e.g., by co-administration with a PD-1 antibody. + This can be achieved by adding a PD-1 antibody during the preparation of T cells, and the PD-1 antibody is preferably a PD-1 monoclonal antibody or a single-chain antibody.
[0008] In a further embodiment, the modified PD-1 + The T cell has an enhanced receptor (ER), which comprises an extracellular domain (ECD) and an intracellular domain (ICD), and the ICD comprises a costimulatory molecule that induces an immune cell activation signal, and the ECD comprises a portion of the immune cell that specifically binds to a target cell. In a specific embodiment, the portion of the immune cell that specifically binds to a target cell is selected from a receptor, ligand, and antibody of a membrane protein of the target cell, or a portion or fragment thereof that has the function of binding to the target cell. Preferably, the ECD comprises a partial sequence of PD1 or an anti-PD-L1 antibody, preferably an anti-PD-L1 scFv, and / or the ICD is derived from CD28.
[0009] Preferably, the modified immune cells have targeting properties for target cells in a subject. In some embodiments, the target cells are tumor cells, particularly cancer cells. In some embodiments, the target cells are host cells infected with a virus, such as a hepatitis virus, preferably hepatitis B virus, hepatitis C virus, hepatitis D virus, or human papillomavirus (HPV). In some embodiments, the target cells of the modified immune cells are selected from one or more of the group consisting of tumor cells, cancer cells, and virus-infected cells.
[0010] In a further embodiment, the modified PD-1 + The T cells express a chimeric antigen receptor (CAR) that specifically recognizes an antigen different from the antigen recognized by the native TCR of the immune cell, preferably CD19.
[0011] In a further embodiment, the modified PD-1 + T cells contain other modifications, such as a death switch.
[0012] In a second aspect, the present application provides a cell population comprising the modified immune cells of the first aspect.
[0013] In a third aspect, the present application provides a method for preparing modified immune cells, said method comprising: (a) PD-1 from peripheral blood + and selecting T cells from (b) PD-1 selected in step (a) + T cells were treated with the following i. knocking out or down the expression of PD-1; ii. Mixing with PD-1 antibody; iii. Expressing reinforcer receptors (ERs); iv. Expressing a chimeric antigen receptor (CAR), and v. Expression of modifications that control cell death, such as death switches, and to carry out one or more of the following: In a preferred embodiment, the treatment in step (b) comprises expressing at least an enhancer receptor (ER). Furthermore, the treatment in step (b) comprises expressing a chimeric antigen receptor (CAR). In another embodiment, or an embodiment based thereon, the treatment in step (b) comprises knocking out or knocking down expression of PD-1 and / or mixing with a PD-1 antibody. Furthermore, the treatment in step (b) comprises expressing a death switch. The treatment can be carried out in vivo or in vitro. The treatment can be carried out before, after, or simultaneously with infusion of the modified immune cells into a subject. In a specific embodiment, the selection in step (a) in the method comprises extracting PD-1 from peripheral blood mononuclear cells in any order. + Cell sorting and CD3 + In a preferred embodiment, the treatment comprises knocking out or knocking down expression of at least i.PD-1.
[0014] In a fourth aspect, the present application relates to modified immune cells prepared by the method of the third aspect.
[0015] In a fifth aspect, the present application relates to a pharmaceutical composition comprising the modified immune cells of the first or fourth aspect, or the cell population of the second aspect.
[0016] In a sixth aspect, the present application relates to the use of the immune cells of the first or fourth aspect or the cell population of the second aspect in a therapy or in the preparation of a medicament, the therapy or medicament being for the treatment of (1) a tumor, and / or (2) Used for treating or preventing a disease or symptom associated with a viral infection, or for preventing the recurrence of a disease or symptom associated with a viral infection. Preferably, the viral infection is a chronic viral infection. In a specific embodiment, the virus is a hepatitis virus, preferably a hepatitis B virus. In another specific embodiment, the virus is a human papillomavirus. The immune cells of the present invention can be used to remove residual viral components in a subject after treatment and prevent the recurrence of viral infection. [Brief explanation of the drawings]
[0017] [Figure 1] FIG. 1 is a photograph showing the tumor-bearing state of PDX mice in Example 1. [Figure 2] FIG. 2 is a photograph showing a tumor-bearing mouse dissected for isolating tumor tissue in Example 1. [Figure 3A] Figure 3A shows the results of an ELISPOT experiment to detect IFNγ secretion using PD-1+ or PD-1- T cells derived from the patient's peripheral blood and co-cultured with the patient's tumor tissue. The results demonstrate the differences in the differentiation and responsiveness of the two types of T cells to tumors. ELISPOT staining photographs and ELISPOT statistical results after 24 hours of co-culture. [Figure 3B] Figure 3B shows the results of an ELISPOT experiment to detect IFNγ secretion using PD-1+ or PD-1- T cells derived from the patient's peripheral blood and co-cultured with the patient's tumor tissue. The results demonstrate the differences in the differentiation and responsiveness of the two types of T cells to tumors. ELISPOT staining photographs and ELISPOT statistical results are shown after 48 hours of co-culture. [Figure 4A] Figure 4A shows the results of in vitro experiments detecting the effect of PD-1 knockout on the function of PD-1+ T cells. PD-1 sorting efficiency detected by flow cytometry. [Figure 4B]Figure 4B shows the results of an in vitro experiment detecting the effect of PD-1 knockout on the function of PD-1+ T cells. TCR expression was detected by flow cytometry, with cells not transfected with TCR-expressing virus (PD-1+NOTD) serving as a control. [Figure 4C] Figure 4C shows the results of an in vitro experiment detecting the effect of PD-1 knockout on PD-1+ T cell function. The effect of PD-1 knockout on PD-1+ T cells expressing and not expressing TCRs, as detected by flow cytometry, with untreated cells and cells subjected to a blank shock as controls for both types of cells. [Figure 4D] Figure 4D shows the results of in vitro experiments detecting the effect of PD-1 knockout on the function of PD-1+ T cells. Secretion of IFNγ (D) and IL-2 (E) by T cells was detected by ELISA experiments after T cells were co-cultured with J82-NY tumor cells. [Figure 4E] Figure 4E shows the results of in vitro experiments detecting the effect of PD-1 knockout on the function of PD-1+ T cells. Secretion of IFNγ (D) and IL-2 (E) by T cells was detected by ELISA experiments after T cells were co-cultured with J82-NY tumor cells. [Figure 5A] Figure 5A shows the results of in vitro experiments detecting the influence of the enriched receptor on the function of PD-1+ T cells. (A) PD-1 sorting efficiency as detected by flow cytometry, (B-C) IFNγ (B) and IL-2 (C) secretion by T cells expressing and not expressing the enriched receptor after co-culture with J82-NY tumor cells as detected by ELISA, and (D) IFNγ secretion by T cells expressing and not expressing the enriched receptor in 96-well plates coated with OKT3 and / or PD-L1 protein as detected by ELISA. [Figure 5B]Figure 5B shows the results of an in vitro experiment detecting the effect of the reinforced receptor on the function of PD-1+ T cells. After co-culture of T cells expressing and not expressing the reinforced receptor with J82-NY tumor cells, IFNγ secretion by T cells was detected by ELISA. [Figure 5C] Figure 5C shows the results of an in vitro experiment detecting the effect of the reinforced receptor on the function of PD-1+ T cells. After co-culture of T cells expressing and not expressing the reinforced receptor with J82-NY tumor cells, IL-2 secretion by T cells was detected by ELISA. [Figure 5D] Figure 5D shows the results of an in vitro experiment detecting the influence of the reinforced receptor on PD-1+ T cell function. IFNγ secretion by T cells expressing and not expressing the reinforced receptor in 96-well plates coated with OKT3 and / or PD-L1 protein was detected by LISA experiments. [Figure 6A] Figure 6A shows the results of an in vivo experiment in mice inoculated with J82-NY-ES01 tumor cells in Example 4, illustrating the effect of enhanced receptors on the tumor-suppressive function of PD-1+ T cells. PBS control. [Figure 6B] Figure 6B shows the results of an in vivo experiment in mice inoculated with J82-NY-ES01 tumor cells in Example 4, illustrating the influence of enhanced receptors on the tumor-suppressive function of PD-1+ T cells. [Figure 6C] Figure 6C shows the results of an in vivo experiment in mice inoculated with J82-NY-ES01 tumor cells in Example 4, demonstrating the effect of enhanced receptor PD-1 on the tumor-suppressive function of PD-1+ T cells. [Figure 6D] Figure 6D shows the results of an in vivo experiment in mice inoculated with J82-NY-ES01 tumor cells in Example 4, demonstrating the effect of enhanced receptor PD-1 TCR T cells on the tumor-suppressive function of PD-1 T cells. [Figure 6E] Figure 6E shows the results of an in vivo experiment in mice inoculated with J82-NY-ES01 tumor cells in Example 4, demonstrating the effect of enhanced receptor PD-1+-V1E-TCR- T cells on the tumor-suppressive function of PD-1+-V1E-TCR- T cells. [Figure 6F] Figure 6F shows the results of an in vivo experiment in mice inoculated with J82-NY-ES01 tumor cells in Example 4, demonstrating the effect of enhanced receptors on the tumor-suppressive function of PD-1+ T cells. The graph summarizes the average values within each group. [Figure 7A] Figure 7A shows the results of the in vivo experiment of Example 4 in mice inoculated with tumor tissue from a colon cancer patient, demonstrating the effect of enhanced receptors on the tumor-suppressive function of PD-1+ T cells. PBS control. [Figure 7B] Figure 7B shows the results of the in vivo experiment of Example 4 in mice inoculated with tumor tissue from a colon cancer patient, demonstrating the effect of enhanced receptor PD-1 on the tumor-suppressive function of PD-1+ T cells. [Figure 7C] Figure 7C shows the results of the in vivo experiment of Example 4 in mice inoculated with tumor tissue from a colon cancer patient, demonstrating the effect of enhanced receptor PD-1+ T cells on the tumor-suppressive function of PD-1+ T cells. [Figure 7D] Figure 7D shows the results of the in vivo experiment of Example 4 in mice inoculated with tumor tissue from a colon cancer patient, demonstrating the effect of enhanced receptor PD-1 on the tumor-suppressive function of PD-1+ T cells. [Figure 8A] FIG. 8A is a diagram showing liver function and HBV-related indices in patients in Example 6. [Figure 8B] FIG. 8B is a diagram showing liver function and HBV-related indices in patients in Example 6. [Figure 8C] FIG. 8C shows liver function and HBV-related indices in control subjects in Example 6. [Figure 9] FIG. 9 shows the biological process of HBV within host hepatocytes. [Figure 10] FIG. 10 shows cytotoxic T lymphocyte (CTL) attack and target cell immune escape. [Figure 11] FIG. 11 shows that ScTILs eliminate residual components of HBV (excluding active virus) in hepatocytes. [Figure 12] FIG. 12 shows the plasmid map of the lentiviral vector construct pLenti-TCR-NY ESO1 for introducing the TCR for NY-ESO-1. [Figure 13] FIG. 13 shows the plasmid map of the lentiviral vector construct pLenti-V1E-T2A-TCR for introducing the enhanced receptor V1E. [Figure 14] FIG. 14 shows the plasmid map of the lentiviral vector construct pLenti-V2E-T2A-TCR for introducing the enhanced receptor V2E. [Figure 15] FIG. 15 is a schematic diagram of the CD19 CAR structure used as an amplifier. [Figure 16] FIG. 16 shows the results of imaging tests before and after treatment for patients 1 to 4 in Example 5. DETAILED DESCRIPTION OF THE INVENTION
[0018] definition Unless otherwise indicated, the practice of the methods disclosed herein employs conventional techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics and recombinant DNA, which are within the skill of the art.
[0019] The term "about" means within an acceptable error range of a particular value as determined by one of ordinary skill in the art, which is determined in part by how the value is measured or determined, i.e., the finiteness of the measurement system. For example, based on practice in the art, "about" can be expressed as within 1 or within more than 1 standard deviation. Alternatively, "about" can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly in biological systems or processes, the term can indicate an order of magnitude of a numerical value, preferably within 5-fold, more preferably within 2-fold. When a particular value is described in this application and claims, unless otherwise specified, the term "about" should be assumed to mean within an acceptable error range of the particular value.
[0020] The term "gene," as used herein, refers to a nucleotide sequence encoding a nucleic acid (e.g., DNA, such as genomic DNA and cDNA) and its corresponding RNA transcription product. Genomic DNA, as used herein, includes intervening non-coding regions and regulatory regions, and can also include the 5' and 3' ends. In some uses, the term includes the transcribed sequence, including 5' and 3' untranslated regions (5'-UTR and 3'-UTR), exons, and introns. In some genes, the transcribed region includes an "open reading frame" that encodes a polypeptide. In some uses of the term, "gene" includes only coding sequences necessary to encode a polypeptide, such as an "open reading frame" or "coding region." In some cases, genes do not encode polypeptides, such as ribosomal RNA genes (rRNA) and transfer RNA (tRNA) genes. In some cases, the term "gene" includes not only the transcribed sequence but also non-transcribed regions, including, for example, upstream and downstream regulatory regions, enhancers, and promoters. A gene can refer to an "endogenous gene" or a native gene in its natural location in the genome of an organism. A gene may refer to a "foreign gene" or a non-native gene. A non-native gene can refer to a gene not normally found in a host organism but that is introduced into the host organism by gene transfer. A non-native gene can also refer to a gene that is not in its natural location in the genome of an organism. A non-native gene can also refer to a naturally occurring nucleic acid or polypeptide sequence that contains mutations, insertions, and / or deletions (e.g., a non-native sequence).
[0021] The term "nucleotide" generally refers to a base-sugar-phosphate combination. Nucleotides can include nucleotide analogs or derivatives and synthetic nucleotides. Nucleotides can be labeled for detection using known techniques. Detectable labels can include, for example, radioisotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels, and enzyme labels.
[0022] The terms "polynucleotide," "oligonucleotide," and "nucleic acid" are used interchangeably and refer to a polymeric form of nucleotides of any length, deoxyribonucleotides or ribonucleotides, or analogs thereof, in single-, double-, or multiple-stranded format. A polynucleotide can be exogenous or endogenous to a cell. A polynucleotide can be a gene or a fragment thereof. A polynucleotide can be DNA or RNA. A polynucleotide can have any three-dimensional structure and can perform any function, known or unknown. A polynucleotide can contain one or more analogs (e.g., modified backbones, sugars, or nucleobases).
[0023] The term "expression" refers to one or more processes by which a polynucleotide is transcribed from a DNA template (e.g., into mRNA or other RNA transcript) and / or by which the transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins. The transcription product and the encoded polypeptide may be collectively referred to as a "gene product." If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in a eukaryotic cell. "Up-regulation" or "down-regulation" of expression generally refers to an increase or decrease in the level of expression of a polynucleotide (e.g., RNA such as mRNA) and / or polypeptide sequence relative to the level of expression in the wild-type state.
[0024] The term "modulation," in reference to expression or activity, refers to changing the level of expression or activity. Modulation can occur at the transcriptional and / or translational level.
[0025] The terms "peptide," "polypeptide," and "protein" are used interchangeably herein and refer to a polymer of at least two amino acid residues linked by peptide bonds. The terms "peptide," "polypeptide," and "protein" are used interchangeably herein and refer to a polymer of at least two amino acid residues linked by peptide bonds. The terms do not refer to a specific length of the polymer, nor do they imply that the polymer is natural, modified, or artificial. In some cases, the polymer may be interrupted by non-amino acids. The terms encompass amino acid chains of any length, including full-length proteins and proteins (e.g., domains) with or without secondary and / or tertiary structure. The terms also encompass modified amino acid polymers, such as those modified by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, oxidation, and any other manipulation, such as conjugation with a labeling component. As used herein, the term "amino acid" generally refers to natural and unnatural amino acids, and may include, but is not limited to, modified amino acids and amino acid analogs. The term "amino acid" includes both D- and L-amino acids.
[0026] The term "fusion" can refer to a protein and / or nucleic acid containing one or more non-native sequences (e.g., moieties). Fusions can include one or more identical or different non-native sequences. Fusions can be chimeric. Fusions can include a nucleic acid affinity tag, a barcode, or a peptide affinity tag. Fusions can provide a signal for localizing a polypeptide to a subcellular location, such as a nuclear localization signal (NLS) for targeting the cell nucleus, a mitochondrial localization signal for targeting the mitochondria, a chloroplast localization signal for targeting the chloroplast, an endoplasmic reticulum (ER) retention signal, etc. Fusions can provide a non-native sequence (e.g., an affinity tag) that can be used for tracking or purification. Fusions can include small molecules, such as biotin, or dyes, such as Alexa Fluor dyes, Cyanine 3 dyes, and Cyanine 5 dyes.
[0027] As used herein, the term "antigen" refers to a molecule or fragment thereof that can be bound by a selective binding agent. For example, an antigen can be a ligand that can be bound by a selective binding agent, such as a receptor. As another example, an antigen can be an antigenic molecule that can be bound by a selective binding agent, such as an immune protein (e.g., an antibody). An antigen can also refer to a molecule or fragment thereof that is used to raise antibodies in an animal that can bind to that antigen.
[0028] As used herein, the term "antibody" refers to a protein-binding molecule with immunoglobulin-like functions. The term antibody includes antibodies (e.g., monoclonal and polyclonal antibodies) and derivatives, variants, and fragments thereof. Antibodies include, but are not limited to, immunoglobulins (Ig) of different classes (i.e., IgA, IgG, IgM, IgD, and IgE) and subclasses (e.g., IgG1, IgG2, etc.). Derivatives, variants, and fragments thereof can refer to functional derivatives, variants, or fragments that retain the binding specificity (e.g., complete and / or partial) of the corresponding antibody. Antigen-binding fragments include Fab, Fab', F(ab')2, variable region fragments (Fv), single-chain variable region fragments (scFv), microantibodies, diabodies, and single-domain antibodies ("sdAb" or "nanobody" or "camelized antibody"). The term antibody includes optimized, engineered, or chemically conjugated antibodies and antigen-binding fragments of antibodies. Examples of optimized antibodies include affinity-matured antibodies. Examples of engineered antibodies include Fc-optimized antibodies (eg, antibodies with optimized crystallizable regions of the fragment) and multispecific antibodies (eg, bispecific antibodies).
[0029] The term "TCR" or "T cell receptor" has the meaning commonly understood in the art. TCRs are the basis for T cell-mediated antigen recognition and are an important part of the immune system. There is a high degree of diversity among TCRs, and the relationship between such diversity and disease is a hot spot of research in the field of immunology. The collection of TCRs that a T cell contains under a given condition or at a given time can be referred to as the TCR population repertoire or TCR profile, and can change dramatically depending on the development and progression of disease.
[0030] The terms "subject," "individual," and "patient" are used interchangeably herein and refer to a vertebrate, preferably a mammal, such as a human. Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets. Additionally, tissues, cells, and the progeny thereof, of a biological entity obtained in vivo or cultured in vitro are included.
[0031] The term "treatment," as used herein, refers to a method for obtaining a beneficial or desired result, including, but not limited to, a therapeutic benefit and / or a prophylactic benefit. For example, treatment can include administration of the modified immune cells of the present invention or a cell population comprising such immune cells. A therapeutic benefit refers to any treatment-related improvement in one or more diseases or symptoms being treated. A prophylactic benefit refers to the fact that the modified immune cells of the present invention can be administered to a subject at risk of developing a particular disease or symptom, or to a subject in whom one or more physiological signs of a disease are present, even if the disease or symptom has not yet manifested.
[0032] The term "effective amount" or "therapeutically effective amount" refers to an amount of a composition, e.g., a composition comprising a modified immune cell, e.g., a lymphocyte (e.g., a T lymphocyte and / or an NK cell), of the present invention, that is sufficient to produce a desired activity when administered to a subject in need thereof.
[0033] immune cells The immune cells of the present invention are derived from peripheral blood, e.g., peripheral blood mononuclear cells (PBMCs), peripheral blood lymphocytes (PBLs), and other blood cell subgroups, including, but not limited to, T cells, natural killer cells, monocytes, monocyte progenitor cells, hematopoietic stem cells, or non-pluripotent stem cells. In some cases, the immune cells of the present invention can be any immune cell, including any T cell, e.g., tumor-infiltrating lymphocytes (TILs). The immune cells can be derived from a subject (e.g., a patient) to be treated. The subject can be a mammal, e.g., a mouse, a monkey, or a human. In a specific embodiment, the immune cells are isolated from peripheral blood mononuclear cells (PBMCs) of a subject, e.g., a human subject.
[0034] T cells can be obtained from blood collected from a subject using any technique, such as Ficoll isolation. Cells from a subject's circulating blood can be obtained by apheresis or leukapheresis. Apheresis products typically contain lymphocytes, including T cells, monocytes, granulocytes, B cells, and other nucleated white blood cells, as well as red blood cells and platelets. Cells collected by apheresis are washed to remove the plasma portion, and then placed in a suitable buffer or medium, such as phosphate-buffered saline (PBS), for subsequent processing. After washing, cells can be resuspended in various biocompatible buffers, such as PBS without Ca or Mg. Alternatively, unwanted components can be removed from the apheresis sample and the cells can be directly resuspended in medium. Samples can be provided directly from the subject or indirectly through one or more intermediaries, such as a sample collection service or a healthcare provider (e.g., a doctor or nurse). In some embodiments, separating T cells from peripheral blood leukocytes can include lysing red blood cells and separating monocytes from peripheral blood leukocytes by centrifugation, for example, using a PERCOL™ gradient.
[0035] Positive or negative selection techniques can further isolate specific subsets of immune cells, e.g., T cells. For example, the immune cells of the present invention are a PD-1-positive T cell subset. Without being limited by any theory, PD-1-positive cells are likely to represent a cell population that has interacted with target cells, and therefore, the cell population is considered to have distinguishing properties from the target cells. In a specific embodiment, immune cells obtained from peripheral blood, e.g., PBMCs, are selected using PD-1 as a marker. For example, PD-1 antibodies can be used to select PD-1 by magnetic sorting (e.g., using magnetic beads) or flow cytometry, preferably using magnetic beads. + The T cells can be selected.
[0036] In the present invention, the selected PD-1-positive T cell subset is the T cell subset that has interacted with the harmful cells intended to be targeted, and therefore the T cells contained therein are believed to have a TCR repatriate or TCR profile capable of specifically recognizing antigens on the harmful cells. To enable T lymphocytes used in cell therapy to recognize harmful cells, such as tumor cells, as targets, one prior art method involves screening the TCR repatriate to obtain a TCR capable of targeting harmful cells, such as tumor cells, and then obtaining the genetic information to genetically modify patient-derived T cells to confer the ability to recognize antigens on the harmful cells. Unlike such techniques that confer differentiation to T cells through exogenous modification, the present invention can ensure the targeting and safety of cells used for therapy by directly selecting T cells from the patient's own cells that are likely to have a TCR specific to the harmful cells, without TCR screening or additionally introducing an exogenous TCR into the T cells used for therapy. Therefore, as will be appreciated by those skilled in the art, the present invention does not require that T cells have one or more specific TCRs, and thus the TCR repertoire can vary widely depending on the patient and their disease state. The present invention only requires that there be differentiation between the T cell population and harmful cells, which is achieved in the present invention primarily by selecting PD-1-positive T cells. For this reason, the methodology of the present invention can be used to target a variety of harmful cells and can also be used to treat a variety of diseases.
[0037] In the context of the present invention, "harmful cells" refers to cells that are targeted and attacked by immune cells, particularly tumor cells, cancer cells, and virus-infected cells.
[0038] The T cells of the present invention can further be CD3-positive, CD4-positive, CD4-negative, or CD8-positive T cell subsets. Any technique known in the art can be used to select cell subsets with or without specific markers. For example, CD3 can be selected using a matrix, such as magnetic beads, to which an antibody against the relevant marker is bound, e.g., CD3 magnetic beads or CD3 / CD28 magnetic beads. + T cells can be selected. Varying the cell concentration can contribute to maximum contact with the substrate surface, e.g., the surface of magnetic beads. Negative selection of cell populations can also be achieved, for example, by using a combination of antibodies against surface markers specific to unwanted cells. A suitable technique includes cell sorting by negative magnetic immunoadhesion, which utilizes a mixture of monoclonal antibodies against cell surface markers present on unwanted cells. For example, CD4 + For cell separation, the monoclonal antibody mixture can include antibodies against CD14, CD20, CD11b, CD16, HLA-DR and CD8.
[0039] In some embodiments, immune cells are cells in the enriched cell population. One or more desired cell types can be enriched by any suitable method, such as by triggering proliferation and / or differentiation of desired cell types, or by arresting the growth of unwanted cell types, or by killing or lysing undesired cell types, or by purifying the desired cell types (e.g., by purifying on an affinity column to retain desired or unwanted cell types based on one or more cell surface markers).
[0040] qualification Upon interaction with target cells, PD-1 + T cells are exhausted and "passivated," and their efficacy and function are somewhat weakened. + By modifying T cells, their effectiveness is restored and improved.
[0041] The PD-1 expression in the modified immune cells of the present invention is knocked out or knocked down. As used herein, "knock-out" of gene expression refers to substantially eliminating expression of the gene. As used herein, "knock-down" of gene expression refers to reducing expression of the gene. In a preferred embodiment, the endogenous PD-1 expression in the modified immune cells of the present invention is knocked out. PD-1 knock-out or knock-down can be achieved using any method known in the art, including, but not limited to, RNAi (including the use of siRNA or shRNA), CRISPR-Cas technology, transcription activator-like effector nuclease (TALEN) technology, site-directed mutagenesis, zinc finger nuclease (ZEN) technology, or a combination thereof.
[0042] In a preferred embodiment, the CRISPR / Cas method is used to knock out endogenous PD-1 in immune cells. The method includes using a guide RNA (gRNA) capable of hybridizing to the target gene PD-1 and a Cas protein or its encoding nucleic acid molecule. In a specific embodiment, an sgRNA targeting PD-1 is used to knock out endogenous PD-1 in immune cells. Preferably, the sgRNA has the nucleotide sequence set forth in SEQ ID NO:4. In a specific embodiment, PD-1 is knocked out using a Cas9 protein or a nucleic acid molecule encoding the same. The Cas9 protein can be derived from Streptococcus pyogenes, Streptococcus thermophilus, or other species. For example, Cas9 can include spCas9, Cpf1, CasY, CasX, or saCas9.
[0043] In one embodiment, the modified immune cells of the present invention include an enhanced receptor (ER). Enhanced receptors can provide additional control over immune cell activity, for example, but not limited to, immune cell activation and amplification. By binding to a ligand, enhanced receptors can generate immune cell activation signals rather than immune cell inactivation signals in the modified immune cells. Inducing immune cell activation signals rather than immune cell inactivation signals in the modified immune cells can minimize immunosuppressive effects in the immune cells. Minimizing immunosuppressive effects in immune cells can enhance the effectiveness of immune cells in immune responses, for example, by increasing immune cell cytotoxicity against target cells (e.g., tumor cells or infected cells).
[0044] The enhanced receptor can comprise an extracellular domain (ECD) of a protein. The protein can be a signaling receptor or any functional fragment, derivative, or variant thereof. In some cases, the signaling receptor can be a membrane-bound receptor. In response to ligand binding, the signaling receptor can induce one or more signaling pathways within the cell. In some cases, the signaling receptor can be a non-membrane-bound receptor. The enhanced receptor can comprise a fragment, e.g., an extracellular domain, of a receptor selected from a G protein-coupled receptor (GPCR), an integrin receptor, a cadherin receptor, an enzyme-linked receptor (e.g., a kinase), a death receptor, a checkpoint receptor, a cytokine receptor, a chemokine receptor, a growth factor receptor, a hormone receptor, and an immune receptor.
[0045] In some embodiments, the enhanced receptor comprises a fragment of an immune checkpoint receptor that can be involved in regulating the immune system. Non-limiting examples of such receptors may include, but are not limited to, PD-1, CTLA-4, BTLA, KIR, IDO, LAG3, TIM-3, TIGIT, SIRPα, and NKG2D, preferably PD-1.
[0046] The enhanced receptor can comprise a fragment that binds to any suitable immune checkpoint receptor ligand. Non-limiting examples of such ligands include, but are not limited to, B7-1, B7-H3, B7-H4, HVEM (herpesvirus entry mediator), AP2M1, CD80, CD86, SHP-2, PPP2R5A, MHC (e.g., class I, class II), CD47, CD70, PD-L1 (or PDL1), and PD-L2. The region of the enhanced receptor that binds to such a ligand can be the natural receptor for such a ligand or a monoclonal antibody for such a ligand.
[0047] The potentiating receptor may also comprise an intracellular domain (ICD), which may be a costimulatory molecule or a fragment, variant, or derivative thereof that induces an immune cell activation signal. In some embodiments, the costimulatory molecule can be used to regulate proliferation and / or survival signals in immune cells. In some embodiments, the ICD is the intracellular domain of a costimulatory molecule, wherein the costimulatory molecule is selected from an MHC class I protein, an MHC class II protein, a TNF receptor protein, an immunoglobulin-like protein, a cytokine receptor, an integrin, a SLAM protein, an NK cell-activating receptor, BTLA, or a Toll ligand receptor. In a preferred embodiment, the costimulatory molecule is a T cell costimulatory molecule, preferably a T cell positive costimulatory molecule, preferably CD28.
[0048] The ECD and ICD of an enhanced receptor can be connected via a transmembrane domain. In some embodiments, the transmembrane domain comprises a polypeptide. The transmembrane polypeptide can have any suitable polypeptide sequence. In some cases, the transmembrane polypeptide comprises the polypeptide sequence of the transmembrane portion of an endogenous or wild-type transmembrane protein, or a variant with at least one amino acid change. In some embodiments, the transmembrane polypeptide comprises a non-natural polypeptide sequence, such as a polypeptide linker sequence. The polypeptide linker can be flexible or rigid. The polypeptide linker can be structured or unstructured. In some embodiments, the transmembrane polypeptide transmits a signal from the ECD, for example, a signal indicating ligand binding, to the ICD. In some embodiments, the ECD comprises a transmembrane domain. In some embodiments, the ICD comprises a transmembrane domain.
[0049] In the method of transfecting the enhanced receptor gene, PD-1 + T cells were electrotransfected with the mRNA of the enhanced receptor or transfected with the enhanced receptor gene PD-1 via lentivirus, adeno-associated virus, or non-viral vectors. + T cells can be transfected.
[0050] The enhanced receptor is a transmembrane protein expressed on the surface of immune cells, and is composed of an extracellular domain (ECD) and an intracellular domain (ICD). The ICD contains a costimulatory molecule that induces an immune cell activation signal, and the ECD can bind to target cells of the immune cells. The PD-1 + It is a part containing the complete sequence structure or binding domain of a membrane protein receptor, ligand, antibody, or any one of the substances that can bind to the target cell of T cells.
[0051] In a specific embodiment, the enhanced receptor is V1E or V2E, the ECD comprises a fragment of PD-1 (e.g., a fragment of the PD-1 extracellular domain) or an scFv sequence of an anti-PD-L1 monoclonal antibody, respectively, and the ICD of the enhanced receptor comprises the intracellular signaling domain of CD28. More preferably, the enhanced receptor comprises the transmembrane region of CD28 or the transmembrane region of CD8. In a most preferred embodiment, the enhanced receptor comprises or consists of a sequence selected from SEQ ID NO:1 or SEQ ID NO:2, or a sequence having at least 75%, 80%, 85%, 90%, 95%, 97%, or 99% identity thereto.
[0052] In some embodiments, the modified immune cells of the present invention comprise a chimeric antigen receptor (CAR). When the CAR can recognize target cells, immune cells, such as T cells, modified with the enhanced receptor have stronger immune cell activation functions than cells not modified with the enhanced receptor. In some cases, the CAR can assist in the expansion of the modified immune cells.
[0053] In a preferred embodiment, the CAR specifically recognizes a different antigen from the native TCR of the immune cell. Preferably, the CAR comprises an antigen-interacting domain (antigen-binding domain) capable of binding to a B cell surface protein, a transmembrane domain, and an intracellular signaling domain. The B cell surface protein can be any protein expressed on the surface of B cells, and is preferably CD19. In some embodiments, the antigen-interacting domain of the CAR can bind to a surface protein on non-B cells, as long as binding to the surface protein does not significantly impair the general health or immune system of the host.
[0054] Non-limiting examples of antigen-binding domains include, but are not limited to, monoclonal antibodies, polyclonal antibodies, recombinant antibodies, human antibodies, humanized antibodies, murine antibodies, or functional derivatives, variants, or fragments thereof, such as, but not limited to, Fab, Fab', F(ab')2, Fv, single-chain Fv (scFv), microantibodies, diabodies, and single-domain antibodies, such as the heavy chain variable domain (VH), light chain variable domain (VL), and variable domain (VHH) of nanobodies derived from camelids. In some embodiments, the antigen-binding domain comprises at least one of Fab, Fab', F(ab')2, Fv, and scFv, preferably scFv. In some embodiments, the antigen-binding domain comprises an antibody mimetic. An antibody mimetic refers to a molecule capable of binding to a target molecule with affinity comparable to that of an antibody. In some embodiments, the antigen-binding domain comprises a transmembrane receptor or any derivative, variant, or fragment thereof. For example, the antigen binding domain can include at least the ligand binding domain of a transmembrane receptor.
[0055] In some embodiments, the antigen-interacting domain of the CAR is capable of binding to a B cell surface protein or fragment thereof, which is coupled (e.g., via covalent and / or non-covalent bonds) to a particle (e.g., a nanoparticle). The particle can be of any particle material, including organic and / or inorganic materials. The particle can have a variety of shapes and dimensions. The particle can be from about 1 nanometer (nm) to about 50 micrometers (μm) in at least one dimension. The particle may be at least about 1 nm, 5 nm, 10 nm, 50 nm, 100 nm, 500 nm, 1 μm, 5 μm, 10 μm, 50 μm, or larger in at least one dimension. The particle may be up to 50 μm, 10 μm, 5 μm, 1 μm, 500 nm, 100 nm, 50 nm, 10 nm, 5 nm, 1 nm, or smaller in at least one dimension. The particles can be nanoparticles, microparticles, nanospheres, microspheres, nanorods, microrods, nanofibers, nanoribbons, etc. Examples of particles include metal nanoparticles (e.g., gold nanoparticles, silver nanoparticles, and iron nanoparticles), intermetallic nanosemiconductor nanoparticles, core-shell nanoparticles, inorganic core particles with polymer shells, organic core particles with polymer shells, and mixtures thereof. Alternatively, the particles can be organic nanoparticles, such as cross-linked polymers, hydrogel polymers, biodegradable polymers, polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), copolymers, polysaccharides, starch, cellulose, chitosan, polyhydroxybutyric acid (PHA), PHB, PHV, lipids, peptides, peptide amphiphiles, polypeptides (e.g., proteins), or combinations thereof. Particles displaying B cell surface proteins on their surface can be introduced into immune cells containing a CAR that binds to the B cell surface protein in vitro. Alternatively or additionally, particles displaying B cell surface proteins can be introduced in vivo (e.g., by local or systemic injection) along with CAR-containing immune cells. These particles can be used to expand CAR-containing immune cell populations in vitro or in vivo.
[0056] In some embodiments, the antigen-interacting domain of the CAR can bind to a B cell surface protein or fragment thereof on a dead B cell. B cell apoptosis can occur before or after the onset of an immune response. Thus, dead B cells or their debris can still display a B cell surface protein or fragment thereof on their surface. The ability of the CAR to target live and dead B cells can increase the probability that modified immune cells containing the CAR will bind to the B cell surface protein and initiate signaling from the intracellular signaling domain. In some cases, signaling from the intracellular signaling domain can promote the expansion (proliferation) of immune cells containing the CAR.
[0057] The intracellular signaling domain of the CAR can induce the activity of modified immune cells. The intracellular signaling domain can transduce effector function signals and guide the cells to perform characteristic functions. The signaling domain can include signaling domains of other molecules. In some cases, truncated portions of signal domains are used in CARs. The intracellular signaling domain can include multiple signaling domains involved in immune cell signaling, or any derivatives, variants, or fragments thereof. The intracellular signaling domain of the CAR can include a costimulatory domain, for example, a costimulatory-derived molecule.
[0058] In a specific embodiment, the CAR of the present application comprises or consists of the sequence of SEQ ID NO:3, or a sequence having at least 75%, 80%, 85%, 90%, 95%, 97% or 99% homology thereto.
[0059] Compared to immune cells lacking a CAR, the included modified immune cells can enhance immune cell proliferation through binding of the CAR to a B cell surface protein. Immune cell proliferation can refer to the amplification or phenotypic change of immune cells. The modified immune cells of the present invention containing a CAR can bind to a B cell surface protein, and their proliferation can be about 5-fold to about 10-fold, about 10-fold to about 50-fold, about 50-fold to about 100-fold, about 100-fold to about 200-fold, about 200-fold to about 300-fold, about 300-fold to about 400-fold, about 400-fold to about 500-fold, about 500-fold to about 600-fold, or about 600-fold to about 700-fold greater than the proliferation of corresponding immune cells lacking a CAR. Proliferation can be determined at least about 12, 24, 36, 48, 60, 72, 84, or 96 hours after contacting the B cells with the modified immune cells containing a CAR. In vitro or in vivo, proliferation can be determined by, for example, measuring the number of immune cells.Methods for measuring the number of immune cells can include flow cytometry, trypan blue exclusion, and / or hemocytometry.Proliferation can also be measured by phenotypic analysis of immune cells.
[0060] The various domains of the enhanced receptors and CARs provided herein can be connected by chemical bonds, such as amide or disulfide bonds, small organic molecules (e.g., hydrocarbon chains), amino acid sequences, such as peptide linkers (e.g., amino acid sequences about 3 to 200 amino acids in length), or combinations thereof. The peptide linker can provide the desired flexibility to allow the chimeric polypeptide to have the appropriate expression, activity, and / or conformational position. The peptide linker can be of any suitable length to connect at least two target domains and is preferably designed to be sufficiently flexible to allow for the appropriate folding and / or function and / or activity of one or both of the domains it connects. In some embodiments, the length of the peptide linker is about 0 to 200 amino acids, about 10 to 190 amino acids, about 20 to 180 amino acids, about 30 to 170 amino acids, about 40 to 160 amino acids, about 50 to 150 amino acids, about 60 to 140 amino acids, about 70 to 130 amino acids, about 80 to 120 amino acids, or about 90 to 110 amino acids. In some embodiments, the linker sequence can comprise an endogenous protein sequence. In some embodiments, the linker sequence comprises glycine, alanine, and / or serine amino acid residues. In some embodiments, the linker can include a GS, GGS, GGGGS, GGSG, or SGGG motif, as well as multiple such motifs, for example, multiple repeated identical motifs. The linker sequence can include any naturally occurring amino acid, non-naturally occurring amino acid, or a combination thereof.
[0061] In some embodiments, the modified immune cells of the present invention further include modifications that regulate immune cell death, such as a death switch. When toxicity is severe, for example, when hypercytokinemia occurs, the death switch can be activated to eliminate the immune cells. When the immune system has an overly intense response, releasing many inflammatory cytokines and causing mild to severe symptoms, including fever, headache, rash, increased heart rate, decreased blood pressure, and difficulty breathing, the death switch can be initiated. The death switch can be a drug-inducible death switch. The death switch can include inducible caspase 9.
[0062] In a preferred embodiment, the modified immune cells of the present invention do not contain an exogenously introduced TCR.
[0063] Any suitable delivery method can be used to introduce the desired compositions and molecules, e.g., polypeptides and / or nucleic acids encoding polypeptides, into immune cells to achieve modification. The various components can be delivered simultaneously or separately. The delivery method can include introducing one or more nucleic acids into immune cells, where the nucleic acids contain nucleotide sequences encoding the compositions of the invention, and can be, for example, expression vectors, e.g., recombinant expression vectors, containing nucleotide sequences encoding target products. Any suitable vector compatible with the host cell can be used in the present invention.
[0064] Non-limiting examples of transfer or conversion methods include, but are not limited to, e.g., viral or bacteriophage infection, transfection, conjugation, protoplast fusion, lipofection, electroporation, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran-mediated transfection, liposome-mediated transfection, particle gun technology, calcium phosphate precipitation, direct microinjection, and nanoparticle-mediated nucleic acid delivery.
[0065] Viral and non-viral gene transfer methods can be used to introduce nucleic acids into mammalian cells or tissues, and can be used in the present invention to introduce target nucleic acids into cells in culture. Non-viral vector delivery systems can include DNA plasmids, RNA (e.g., transcription products), naked nucleic acids, and nucleic acids incorporated into delivery vectors such as liposomes. Viral vector delivery systems can include DNA and RNA viruses, which may or may not be integrated into the cell's genome after delivery to the cell.
[0066] RNA or DNA virus-based systems can be used to target specific cells in the body and deliver viral payloads to the cell nucleus. Viral vectors can be administered directly (in vivo) or used to treat cells in vitro, and optionally administered to cells (ex vivo). Viral-based systems can include retroviral, lentiviral, adenoviral, adeno-associated viral, and herpes simplex viral vectors used for gene transfer. Integration into the host genome can occur using retroviral, lentiviral, and adeno-associated viral gene transfer methods, resulting in long-term expression of the inserted transgene. High transduction efficiency can be observed in many different cell types and target tissues. Lentiviral vectors are preferably used in the present invention.
[0067] In some aspects, the present invention provides methods for modifying immune cells, including methods for delivering to immune cells one or more polynucleotides, or one or more vectors described herein, or one or more transcripts thereof, and / or one or more proteins transcribed therefrom. In some embodiments, the disclosure further provides modified immune cells produced by these methods, and includes those immune cells.
[0068] target cell The modified immune cells of the present invention can target and act on various target cells in vitro, in vivo, or ex vivo. The target cells can be isolated cells. The target cells can be cells in a living organism. The target cells can be cells in a cell culture.
[0069] The target cell can be a mammalian cell or a cell derived from a mammal, and the mammal can be a rodent, a primate such as a human, etc. The target cell can be derived from a prokaryotic cell, e.g., a bacterial cell, an archaeal cell, or a eukaryotic cell.
[0070] The target cell can be a cell infected with a pathogen, and the pathogen can be a microorganism, including but not limited to bacteria, fungi, or viruses. The target cell can be a host cell, for example, a host cell of the pathogen. In a specific embodiment, the target cell is, for example, a cell infected with a hepatitis virus or a human papillomavirus, and the hepatitis virus is preferably a hepatitis B virus.
[0071] The target cell may be from a particular organ or tissue. The target cell may be a single-cell organism.
[0072] The target cells can be stem or progenitor cells, including, but not limited to, adult stem cells, embryonic stem cells, induced pluripotent stem cells (iPSCs) and progenitor cells, such as cardiac progenitor cells, neural progenitor cells, etc. The target cells can be pluripotent stem cells.
[0073] The target cell may be a genetically modified cell. The target cell may comprise a target nucleic acid.
[0074] The target cells can be diseased cells, e.g., cells derived from a diseased subject. The diseased cells can have altered metabolism, gene expression, and / or morphological characteristics. The diseased cells can be cancer cells or virus-infected cells.
[0075] In a preferred embodiment, the target cells are tumor cells, particularly cancer cells. The tumors include solid tumors and hematological tumors, and are preferably solid tumors.
[0076] therapeutic use The modified immune cells of the present invention can be used to treat tumors, i.e., can be used together with tumor cells as target cells. In some embodiments, the target cells form tumors. Treatment with the modified immune cells of the present invention can result in stable tumor growth, non-progression, and / or non-metastasis. For example, "stable growth" means that the volume of one or more tumors does not increase by more than 1%, 5%, 10%, 15%, or 20% during a period of time following treatment. In some embodiments, the period of time is at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more weeks, preferably at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more months, and more preferably at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more years. In some embodiments, treatment with the modified immune cells of the present invention can reduce tumor size or tumor cell count by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more. In some embodiments, the tumor is completely eliminated or reduced to below the level of detection. In some embodiments, the subject remains tumor-free for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more weeks, preferably at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more months, and more preferably at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more years following treatment.
[0077] When used to treat tumors, the amount of modified immune cells of the present invention administered to a subject is 10 4 From 10 10 Between 10 4 From 10 9 Between 10 5 From 10 8 Between 10 6 From 10 7 The PD-1 of the present invention +If the T cells contain a modification of an expander, e.g., a CD19 CAR, the total amount infused will be the PD-1 T cells of the present invention without said modification. + This is because the CD19 CAR contributes to the expansion of the infused immune cells in the patient's body, and this effect is described in detail in Example 5. For example, the PD-1 + If the T cells contain an expander modification, e.g., CD19 CAR, the total amount of cells infused can be 10 4 From 10 9 Between 10 5 From 10 8 Between 10 6 From 10 7 The modified immune cells of the present invention can be infused into a subject in one or more infusions, for example, one, two, three, or four infusions. The amount of immune cells in each infusion can be the same or different.
[0078] The modified immune cells of the present invention can be used to treat diseases or symptoms associated with viral infection, i.e., target virally infected cells. In some embodiments, the immune cells of the present invention can treat cancer in a patient while simultaneously eliminating viruses in the patient's body, e.g., residual viruses after antiviral therapy. Thus, the modified immune cells and methods of the present invention are particularly suitable for patients known to be infected with a virus. The viral infection may or may not be associated with cancer. In another embodiment, the immune cells of the present invention are specifically used to treat virally infected cells for the treatment of viral-related diseases and / or the elimination of viruses.
[0079] In a preferred embodiment, the viral infection is hepatitis B virus infection.For example, the viral infection is chronic hepatitis B virus infection, for example, the period of hepatitis B virus infection in the liver lasts for more than 6 months.Diseases associated with chronic hepatitis B virus infection include liver cirrhosis and hepatocellular carcinoma.
[0080] In another preferred embodiment, the viral infection is human papillomavirus (HPV) infection. To date, more than 100 types of human papillomavirus have been discovered. Depending on whether they are associated with cancer, they are generally divided into high-risk types (including, but not limited to, types 16, 18, 31, 45, 52, and 84) that cause cancer and low-risk types (e.g., types 6, 11, 42, 43, and 44 that cause genital warts). HPV causes proliferation of squamous epithelium in human skin and mucous membranes, leading to diseases of the skin, respiratory tract, oral cavity, gastrointestinal tract, eyes, anus, and urogenital tract. HPV-associated diseases include, but are not limited to, warts (e.g., common warts, flat warts, and genital warts), tumors, or cancers (e.g., squamous cell carcinoma, cervical cancer, vulvar cancer, vaginal cancer, penile cancer, anal cancer, and oropharyngeal cancer).
[0081] Target cell death can be determined by any suitable method, including, but not limited to, counting cells before and after treatment or measuring the levels of markers for live or dead cells. Cell death can be determined by any suitable method. In some embodiments, cell death is determined relative to initial conditions. For example, an individual can have a known initial amount of target cells, such as an initial cell mass of known size or a known concentration of circulating target cells. In such cases, cell death can be expressed as the ratio of live cells to the initial cell population after treatment. Various cell death assays are available, and various detection methods are available. Examples of detection methods include, but are not limited to, cell staining, microscopy, flow cytometry, cell sorting, and combinations thereof.
[0082] After the treatment period, if the tumor is surgically removed, the effectiveness of the treatment in reducing tumor size can be determined by measuring the percentage of necrotic (i.e., dead) resected tissue. In some embodiments, treatment is effective when the necrotic rate of the resected tissue is greater than about 20%, for example, at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%. In some embodiments, if the necrotic rate of the resected tissue is 100%, active tumor tissue is absent or undetectable.
[0083] Exposure of target cells to the modified immune cells disclosed herein can be carried out in vitro or in vivo. Exposure of target cells to modified immune cells generally refers to contacting and / or bringing the target cells into sufficient proximity with the modified immune cells so that antigens (e.g., membrane-bound or non-membrane-bound antigens) on the target cells can bind to receptors, including enhanced receptors and / or CARs, expressed on the immune cells. Modified immune cells can be exposed to target cells in vitro by co-culturing the target cells with the modified immune cells. Co-culturing can be carried out as parietal cells or in suspension. The target cells and modified immune cells can be co-cultured in various suitable cell culture media, for example, with supplements, growth factors, ions, etc. In vivo exposure of target cells to modified immune cells can be achieved, for example, by administering the modified immune cells to a subject, e.g., a human, and allowing the modified immune cells to localize to the target cells via the circulatory system. In some cases, the modified immune cells can be delivered to the area where the target cells are located, for example, by direct injection. The exposure can be for any suitable period of time, such as at least 1 minute, at least 5 minutes, at least 10 minutes, at least 30 minutes, at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 7 hours, at least 8 hours, at least 12 hours, at least 16 hours, at least 20 hours, at least 24 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 1 month or more. [Example]
[0084] For a full understanding and utilization of the present invention, the present invention will be described in detail in the following with reference to examples and the accompanying drawings. The examples are intended to illustrate and explain the present invention only and are not intended to limit the scope of the present invention, which is specifically limited by the appended claims.
[0085] Example 1. PD-1 in cancer patients + Verification of tumor recognition characteristics by T cells Cancer patient peripheral blood PD-1 + To verify the tumor-specific differentiation properties of T cells, we processed tumor tissue from the same patient and established a patient-derived tumor xenograft (PDX) mouse model. The specific process is as follows:
[0086] I. Tumor Implantation 1. Fresh tumor samples collected from colon cancer patients during surgery were transferred into a 60 mm sterile Petri dish, and the tumor was washed with PBS containing an appropriate amount of 1% penicillin-streptomycin.
[0087] 2. Tumor samples were cut into 3 mm x 3 mm x 3 mm pieces using a sterile surgical blade and subcutaneously implanted into 6-8 week-old NPI (genetic background NOD-Prkdcem1Idmo-il2rgem2Idmo) male mice.
[0088] 3. Before transplantation, an anesthetic was injected intraperitoneally into the NPI mice. After waiting for the mice to become anesthetized, an approximately 1 cm opening was made in the skin on the upper outer side of the right hind leg of the mice using sterile ophthalmic scissors. The tumor mass was then pushed out subcutaneously on the outer side of the right hind leg using ophthalmic forceps, and the surgical incision was then closed.
[0089] II. Tumor observation 1. After tumor formation, the tumor was designated as the P0 generation. The tumor's major axis a and minor axis b were measured using a caliper, and the formula (V) was used: (V) = 1 / 2 × a × b 2 Tumor volume was calculated by:
[0090] 2.P0 tumor is 800-1000mm 3When the tumors reached a size of 1 mm, they were excised, necrotic tissue was removed, and the tumors were recut into 3 mm x 3 mm x 3 mm pieces. The above process was repeated to implant them subcutaneously into NPI mice for tissue passage. After tumor formation, the tumors were designated as the P1 generation (the tumor-bearing status of the mice is shown in Figure 1). This process was repeated until the tumors reached the P3 generation. Tumor tissues were excised from three mice each, and subsequent in vitro functional experiments were performed (the dissected tumor tissues are shown in Figure 2).
[0091] 3. Tumor samples obtained at each generation can be used for genomics, proteomics, and pathological analysis, while slow-frozen samples can be reserved and resuscitated for subsequent experimental needs.
[0092] III.PD-1 + T and PD-1 - T cell sorting When the PDX mouse model was passaged to the third generation, peripheral blood PD-1 from the same patient was + T cells and PD-1 - T cells were selected.
[0093] IIIa.PD-1 + T cell sorting 1. Predicted and selected PD-1 + Cell count and PD-1 + Based on the ratio of cells, the corresponding number of PBMC cells was taken out into a centrifuge tube. 2. The cells were resuspended and washed by adding sufficient saline, centrifuged at 600 g for 10 minutes, and the supernatant was discarded. 3. Repeat step 2 and wash twice with saline to obtain a cell pellet. 4.1×10 7 Add 40 μl of buffer solution per 1 x 10 cells and resuspend. 6 2 μl of anti-PD-1-Biotin antibody (Biolegend, Cat#329934) was added for every 10 viable cells, mixed evenly, and then incubated at 4°C for 10-15 minutes in the dark. 5.1×10 7The cells were washed by adding 0.5 to 1 ml of buffer solution per total number of cells, centrifuged at 600 g for 10 minutes, and the supernatant was absorbed and discarded. 6.1×10 7 Add 80 μl of buffer per total cells and resuspend 1 x 10 cells. 7 20 μl of anti-Biotin MicroBeads (Meltenyi, Cat#130-090-485) was added for every 100 viable cells, mixed evenly, and then incubated at 4° C. for 15 minutes in the dark. 7.1×10 7 The cells were washed by adding 1 to 2 ml of buffer for each total number of cells, centrifuged at 600 g for 10 minutes, and the supernatant was absorbed and discarded. 8.1×10 8 The cells were resuspended by adding 1 ml of buffer per total number of cells. 9. The LS-type selection column was placed on a magnetic holder, and a 15 ml centrifuge tube was placed underneath. The column was rinsed once with 3 ml of buffer solution, and then replaced with a new 50 ml centrifuge tube as a collection tube. 10. The cells resuspended in step 8 were evenly added to the LS-type column. After the cells had passed through the column, the column was washed with 3 ml of buffer three times to remove unadsorbed cells, i.e., PD-1. - PBMC cells were collected, counted, and analyzed for subsequent PD-1 - Used for selecting T cells. 11. The LS-type selection column was removed from the magnetic holder and placed on a new 15 ml centrifuge tube. 12.5 ml of buffer solution was added to the column, and the liquid in the column was quickly pushed out using a piston to collect the cells labeled with magnetic beads and detect PD-1. + The cells were counted for further use. 13. PD-1 selected in steps 10 and 12, respectively - and PD-1 + 5 × 10 cells each 5 Individual cells were removed and labeled with CD3-APC antibody for flow cytometry detection. 14. According to the experimental needs, an appropriate amount of PD-1 +The cells were removed and centrifuged at 600 g for 10 min, and the cells were resuspended in complete medium. 15. Resuspended PD-1 + T cells were activated by adding CD3 / CD28 DynaBeads (Gibco, Cat#40203D) and subcultured.
[0094] IIIb. PD-1-T cell selection 1.CD3 flow cytometry detects PD-1 - The percentage of T cells in PBMCs was detected, and the total T cells were calculated according to cell counts. 2. Based on the number of T cells and the ratio of T cells to CD3 / CD28 DynaBeads of 1:3, the appropriate number of CD3 / CD28 DynaBeads was removed into a 15 ml centrifuge tube and placed on a magnetic holder to remove the storage solution. 3. The centrifuge tube was removed from the magnetic holder, and CD3 / CD28 DynaBeads resuspended in medium (10x volume) were added, and the tube was placed on the magnetic holder, and the medium was removed. 4. Repeat step 3 twice, using 1-5 ml of medium once to resuspend the CD3 / CD28 DynaBeads. 5. Add 1 / 2 of the resuspended CD3 / CD28 DynaBeads to the suspended cells to achieve a cell concentration of 3.35–15 × 10 6 The solution was adjusted to 1 / ml and added to new centrifuge tubes (15 to 50 ml for 50 ml centrifuge tubes, 2 to 15 ml for 15 ml centrifuge tubes). 6. The centrifuge tube was placed on a hybridization furnace (1 rpm / min) and cultured at room temperature (18-20°C) for 30 minutes. 7. The centrifuge tube was carefully placed on a magnetic holder and left to stand for 2 minutes to collect the T cells bound to the CD3 / CD28 DynaBeads, which were then resuspended in an appropriate amount of medium and counted. 8. Repeat steps 5 to 7 with the unadsorbed cell suspension to collect T cells bound to CD3 / CD28 DynaBeads for the second time, resuspend them in an appropriate volume of medium, and count them. 9. The unadsorbed cell suspension was counted and stored frozen. 10. The CD3 / CD28 DynaBeads-bound T cells collected in both steps 7 and 8 were combined and incubated at a cell density of 1.2 x 10 6 / ml and Tscm was added (T150 100-120ml, T75 50-60ml, T25 15-29ml). 11. The mixture was mixed thoroughly and placed in a CO2 incubator for subculturing.
[0095] IV. Detection of T cell activation Tumor tissues were isolated from the three P3 generation mice obtained in Part II above, minced, and single-cell suspensions were prepared by enzymatic digestion. These were designated as 1# tumor tissue, 2# tumor tissue, and 3# tumor tissue, respectively. - T cells and PD-1 + T cells were co-cultured with each of the three tumor tissue cells to form six cultures, and ELISPOT experiments were performed on these six cultures at 24 and 48 hours to detect IFN-γ and examine the activation status of different T cells.
[0096] As shown in Figure 3A-B, PD-1 + T cell IFN-γ release is regulated by PD-1 - This is significantly higher than that of T cells, which is due to PD-1 + T cells are activated by tumor tissue and express PD-1 - This means that T cells cannot be activated. + It has been demonstrated that T cells can effectively identify tumor cells, generate an immune response against them, and initiate killing. T cells capable of exerting immune functions against tumor cells (tumor-specific T cells) exist in the peripheral blood of patients, and these cells are mainly expressed by PD-1. + It explains that it is concentrated in the ingredients.
[0097] Example 2. PD-1 by PD-1 knockout +Improved T cell function PD-1 knockout leads to PD-1 + By removing the "suppressive state" of T cells, PD-1 + In order to verify whether NY-ESO-1 can effectively improve T cell function, the inventors conducted the experiment in this example. The inventors established an in vitro model using tumor cells characterized by the expression of NY-ESO-1 and corresponding PD-1, which contains a TCR capable of binding to NY-ESO-1. + They constructed TCR-T cells and used CRISPR-Cas9 technology to knock out the PD-1 gene in T cells to observe the effects on tumor cells.
[0098] First, the patient's white blood cells are apheresed and PD-1 is detected. + PD-1 monoclonal antibody was added to select T cells, and the selection efficiency is shown in Figure 4A.
[0099] Then, the selected PD-1 + CD3 / CD28 DynaBeads were added to the T cells and cultured overnight. The next day, PD-1 + T cells were divided into two groups: one group was NOTD-T without viral transfection, and the other group was TCR-T, which was transfected with a lentiviral vector expressing a TCR that recognizes NY-ESO-1 (pLenti-TCR-NYESO1, the plasmid structure is shown in Figure 12) at an MOI (number of lentiviruses / number of cells) of 2. T cells were cultured and expanded, and the expression rate of the TCR was detected by flow cytometry at 40.1% (Figure 4B).
[0100] On day 4 after lentivirus addition, the CD3 / CD28 DynaBeads were removed, and on day 5, the PD-1 sgRNA and Cas9 protein were electrotransferred to the PD-1 cells. + NOTD-T cells and PD-1 +We introduced NOTD-T cells into TCR-T cells to knock out endogenously expressed PD-1, with untreated and blank shock groups serving as controls. As shown in Figure 4C, PD-1 expression was detected by flow cytometry 7 days after electrical transfer. The PD-1 positivity rates in the untreated and blank shock groups were 39.6% and 34.8%, respectively. After PD-1 knockout, the PD-1 positivity rate decreased to 3.6%. The PD-1 positivity rates in the untreated and blank shock groups were 40.1% and 37.9%, respectively. After PD-1 knockout, the PD-1 positivity rate decreased to 4.0%, demonstrating a relatively good knockout effect, allowing further experiments to be performed.
[0101] PD-1 knockout PD-1 + To verify the effect on T cell function, ELISA experiments were performed. Different groups of T cells were co-cultured with bladder cancer cell line J82 or J82-NY-ESO1 (J82-NY) tumor cells overexpressing NY-ESO-1 protein for 24 hours, and IFN-γ and IL-2 secretion were detected by ELISA. As shown in Figures 4D and 4E, knockout of PD-1 significantly reduced PD-1 expression. + The PD-1 knockout cells were transfected with a viral vector expressing TCR and co-cultured with J82-NY-ESO1 tumor cells. When compared with two controls (untreated and blank shock), the PD-1 knockout cells significantly promoted cytokine secretion in TCR-T cells. + T cell IFN-γ secretion increased by nearly 50% and IL-2 secretion increased by more than 80%, and knocking out PD-1 significantly reduced PD-1 + It has been shown that it can effectively improve the immune efficacy of T cells.
[0102] Example 3. Enhanced receptor PD-1 + Improvement of T cell function (in vitro experiment) In cell therapy for solid tumors, it has been proposed to introduce an enhanced receptor containing an extracellular domain of the immune cell capable of binding to a target cell and an intracellular domain of a T cell costimulatory molecule into T cells used for treatment in order to remove the inhibitory effect of inhibitory receptors, such as PD-1, on immune cells and further improve the efficacy of T cells, as previously described by the applicant in PCT / CN2020 / 073017.
[0103] PD-1 receptors are obtained by the methods of the present invention + To examine whether or not this has an effect on the immune efficacy of T cells, the inventors investigated the following three PD-1 antibodies containing TCRs targeting the tumor target NY-ESO-1: + T cells were constructed.
[0104] 1.PD-1 containing TCR targeting NY-ESO-1 + TCR-T cells. 2. PD-1 containing TCR targeting the enhanced receptor V1E and NY-ESO-1 + V1E-TCR-T cells, wherein V1E comprises a partial sequence of PD1 as an extracellular domain and also comprises the transmembrane and intracellular domains of CD28, and the sequence of V1E is, for example, as shown in SEQ ID NO:1. 3. PD-1 containing TCR targeting the enhanced receptor V2E and NY-ESO-1 + The V2E-TCR-T cells include V2E, which comprises an scFv antibody sequence capable of binding to PD-L1 protein as an extracellular domain, and also comprises the transmembrane and intracellular domains of CD28, and the sequence of V2E is, for example, as shown in SEQ ID NO:2.
[0105] PD-1 without TCR targeting NY-ESO-1 and any enhanced receptor + NOTD-T cells were used as a control. The specific construction process is as follows.
[0106] First, the patient's white blood cells are apheresed, and PD-1 monoclonal antibody is added to the cells.+ T cells were sorted. The sorting efficiency is shown in Figure 5A. Then, PD-1 + CD3 / CD28 DynaBeads were added to the T cells and cultured overnight. The next day, PD-1 + T cells were divided into four groups: Group 1: NOTD-T, no viral transfection. Group 2: TCR-T, a lentiviral vector expressing a TCR that recognizes NY-ESO-1, was added. Group 3: V1E-TCR-T, a lentiviral vector expressing V1E-TCR was added. The vector structure is shown in Figure 13. Group 4: V2E-TCR-T, a lentiviral vector expressing V2E-TCR was added. The vector structure is shown in Figure 14.
[0107] To groups 2 to 4, lentivirus was added at an MOI (number of lentiviruses / number of cells) of 2, and T cells were cultured and expanded.
[0108] Enhanced receptor PD-1 + To verify the effect on T cell function, ELISA experiments were performed. The inventors co-cultured different groups of T cells with J82 tumor cells or J82-NY-ESO1 tumor cells overexpressing NY-ESO1 for 24 hours, and then detected the secretion of IFN-γ and IL-2 by ELISA. As shown in Figures 5B and 5C, the enhanced receptor V1E inhibited PD-1. + Both V1E and V2E receptors can significantly promote IFN-γ secretion in TCR-T cells, and both V1E and V2E receptors can promote PD-1 + It can significantly promote IL-2 secretion from TCR-T cells, and both types of enhanced receptors effectively inhibit PD-1 + It has been shown to improve T cell function.
[0109] Enhanced receptor PD-1 +To further examine the effects on T cell function, the four groups of T cells were plated in 96-well plates coated with OKT3 (a CD3 antibody), PD-L1 protein, or OKT3 + PD-L1 protein. After 48 hours of incubation, the supernatants were collected and IFN-γ secretion was measured by ELISA. As shown in Figure 5D, OKT3 effectively stimulated T cell IFN-γ secretion. When stimulated with OKT3 and PD-L1 protein, the amount of IFN-γ secreted by TCR-T and NOTD cells was reduced to a certain extent. This was due to PD-L1 binding to PD-1 protein on the T cell surface, suppressing T cell function. This also simulates the suppression of T cell function by PD-L1 on target cells. In contrast, not only were the T cell functions of receptors with enhanced expression not inhibited by PD-L1 protein, but T cells with receptors with enhanced expression treated with OKT3 and PD-L1 simultaneously had significantly higher IFN-γ secretion than those treated with OKT3 alone, indicating that when PD-L1 protein binds to V1E or V2E-enhanced receptors, contact with PD-L1 itself not only suppresses T cells but also significantly promotes cytokine secretion by T cells. These results support the PD-1 protein obtained by the present invention. + T cell-expressed enhanced receptor efficiently converts the inhibitory signal of PD-L1 into an activating signal for T cells, leading to PD-1 + It has been shown to enhance T cell function.
[0110] Example 4. Enhanced receptor PD-1 + Improvement of T cell function (in vivo experiment) Enhanced receptor PD-1 + To further examine the effects of T cells on tumor-suppressive function in vivo, we constructed two systems: one containing mice implanted with a tumor cell line and T cells expressing a TCR and enhanced receptor capable of recognizing the tumor cell line, and the other containing tumor cells from a patient with a solid tumor and T cells from the same patient.
[0111] 1. Test using mice inoculated with the J82-NY-ESO1 tumor cell line First, 20 NSG mice were inoculated with the J82-NY-ESO1 tumor cell line. The average tumor volume was 100 mm. 3 When the age reached 18.5 years, the 20 mice were randomly divided into 5 groups with 4 mice in each group.
[0112] At the same time, PD-1 was detected in the peripheral blood of tumor patients. + T cells are selected, and the negative components selected at the same time are treated with PD-1 - T cells were defined as PD-1 after selection. + T and PD-1 - T cells were transfected with lentiviruses expressing TCR (a TCR that recognizes NY-ESO1) and V1E-TCR at an MOI of 2, and PD-1 was expressed as described in Example 3. - TCR-T, PD-1 + TCR-T and PD-1 + V1E-TCR-T cells were prepared, in which PD-1 + NOTD (non-virally transfected PD-1+ T cells) served as a control.
[0113] After the cells were prepared, they were infused into four groups of mice, with one group of mice receiving PBS as a blank control. The length, width, and height of the subcutaneous tumors were measured at various time points after infusion, and the tumor volume in the mice was calculated.
[0114] The results are shown in Figure 6. + Tumors in mice infused with NOTD cells grew persistently (Figures 6A and 6B), with tumor volumes reaching 500 mm 44 days after T cell infusion. 3 The other three groups of mice had PD-1 - TCR-T, PD-1 + TCR-T and PD-1 + Infusion of V1E-TCR-T cells reduced tumor volume to a certain extent in all cases (Fig. 6C-E), and PD-1 +The effect of V1E-TCR-T cells was most evident, with almost complete elimination of the tumor.
[0115] Figure 6F shows the mean tumor volume curves for each group. - TCR-T, PD-1 + TCR-T and PD-1 + The mean tumor volume of mice in each group injected with V1E-TCR-T cells was 25.43 mm 3 , 102.4mm 3 and 0 mm 3 Both of these showed relatively good tumor suppression effects.
[0116] As mentioned above, PD-1 + The tumor-suppressing effect of V1E-TCR-T cells was the strongest, completely eradicating tumors in all four mice, achieving a 100% complete response. - The tumor suppression effect of PD-1 is even better than that of TCR-T. + Enhanced receptors carried in T effectively inhibit PD-1 + It can improve T cell function and inhibit the tumor suppression effect of PD-1. - PD-1 is not as effective on T cells + Reverses T cell exhaustion and does not express the potentiating receptor PD-1 - They have been shown to produce even greater efficacy than T cells.
[0117] 2. Test using mice transplanted with patient tumor tissue Similar experiments were performed using mice implanted with patient-derived tumor tissue and T cells from the same patient.
[0118] The inventors constructed a patient-derived tumor xenograft (PDX) model from tumor tissue derived from a patient with solid tumor. When the PDX model was passaged to the fifth generation, 20 mice were selected, and the average tumor volume was 100 mm. 3 When the number of mice reached 100, the 20 mice were randomly divided into 4 groups with 5 mice in each group.
[0119] At the same time, PD-1 was detected in the peripheral blood of the same patient. + T cells are selected, and the negative components after simultaneous selection are identified as PD-1 - T cells were defined as a subset of selected PD-1 + T cells were transfected with lentivirus at an MOI of 2 to express the enhanced receptor V2E (the construct is the same as the lentiviral vector expressing V2E-TCR in Example 3, but does not contain the TCR-encoding fragment), and PD-1 - -T, PD-1 + -T and PD-1 + V2E-T cells were prepared.
[0120] After the cells were prepared, they were infused into three groups of mice, and one group of mice was infused with PBS as a blank control. After the infusion, the tumor volumes in the mice were measured at various time points.
[0121] The tumor growth patterns of various mice in each group were compared, and the results are shown in Figures 7A-C. Because patient-derived tumor tissue was directly implanted, the tumor tissue implanted into each mouse may have relatively large heterogeneity in cellular composition compared to the cell lines used above, and there were some differences in the results between different mice in the same group. Therefore, in this experiment, we did not calculate and compare the average values of each group as in previous experiments.
[0122] Nevertheless, as can be seen from Figure 7, PBS and PD-1 - -T, PD-1 + All tumors in mice infused with PD-1 T cells continued to grow rapidly and did not show any tumor suppressive effect. + In mice injected with V2E-T cells, tumor volume decreased in three of the five mice, and in two of these mice, tumor volume decreased to the initial 94 mm. 3 and 85mm 3to 21mm respectively 3 and 52mm 3 (Fig. 7D).
[0123] The results are consistent with PD-1 + By carrying enhanced receptors on T cells, PD-1 - Effectively improves T cell function and inhibits PD-1 + It has been shown to reverse T cell status and promote tumor suppression in the body.
[0124] Example 5. Enhanced receptor and CAR-modified PD-1 + First clinical trial of T cells In the context of this application, PD-1 in the peripheral blood of patients with advanced tumors - These T cells are thought to be T cells that once infiltrated tumors, were suppressed by the tumor microenvironment, and then returned to the peripheral blood, and are called cTILs (circulating tumor infiltrating lymphocytes).
[0125] Nine patients (referred to as subjects) with advanced solid tumors for whom conventional treatments were ineffective were enrolled in a clinical trial study, and PBMCs from the patients were collected and PD-1 + T cells (cTIL) were isolated and genetically modified to express the V1E-enhanced receptor and amplification factor (CD19CAR, the sequence of which is shown in SEQ ID NO:3), to prepare super cTIL (ScTIL), which were then infused into patients.
[0126] 1. Subject Selection The clinical status of the patients before treatment is shown in the table below.
[0127] [Table 1]
[0128] In the above table, TMB represents tumor mutation burden, which is measured as the number of mutations per million bases in the genome, with a value of less than 5 representing a low mutation burden, 5 to 10 representing a medium mutation burden, and 10 or more representing a high mutation burden. In this field, it is generally believed that a higher TMB is more suitable for immunotherapy, and a lower TMB is less suitable for such therapy.
[0129] As can be seen from the table above, the selected patients were solid tumor patients with eight different types of cancer (gallbladder cancer, ovarian cancer, lung cancer, colon cancer, pancreatic neuroendocrine tumor, renal cancer, mucosal melanoma, and pancreatic cancer). All of these patients were in the terminal stage, had not responded to conventional multi-line therapy, had numerous distant metastatic lesions in their bodies, and most of the patients did not have high levels of TMB.
[0130] 2. Pre-treatment Cell Preparation 2.1 PD-1 + Isolation of T (cTIL) cells: (1) Peripheral blood mononuclear cells were apheresed from patients, and PBMCs were isolated. PD-1 was detected by flow cytometry. + T cells (PD-1 + CD3 + double-positive cells) were found in all T cells (CD3 + The percentage of PD-1 in the total number of cells was detected (see table below). + The proportion of PD-1 T cells among total T cells was identified as 28.5% (patient 1) and 14.3% (patient 2) (Table 2). + The T cells are considered to be TILs derived from tumor tissue, and because they enter the peripheral blood from the tumor tissue, they are called cTILs (circulating TILs). (2) PD-1 using the above method + T cells were sorted.
[0131] 2.2 Preparation of ScTILs: Super cTILs (ScTILs) were prepared by transfecting cTIL cells with a composite lentivirus simultaneously carrying V1E-CD19 CAR. The lentivirus transfection process was the same as that described in Example 3. After 8-10 days of natural amplification, the CAR in the cells was detected using flow cytometry. + The percentage of cells (considered effective cells) was detected, and the effective cell rate was 10% to 40%. After quality control inspection, the cells were loaded into transfusion bags. The entire preparation process took only 8 to 10 days (the process of identifying differentiated T cells that do not contain new antigen components).
[0132] 3. Infusion therapy and monitoring: All patients received intravenous infusion of ScTILs. The translucent, pale yellow ScTIL cell suspension used for intravenous infusion was resuscitated at the bedside using a 38.5°C water bath and then rapidly infused intravenously. The infusion volume was determined according to the total cell volume, which was 6.9 × 10 5 ~4.5×10 8 The infusion volume was 20–40 ml, and the cell density was approximately 3 × 10 6 ~3×10 7 / ml, and the total effective cell (CAR-positive cell) transfusion volume is shown in Table 2. After transfusion, the patient continued to be observed in hospital.
[0133] 3.1 Safety Assessment Of the nine subjects, only three developed high fever, one of whom experienced spontaneous remission, and the other two experienced symptomatic remission after tocilizumab treatment. The incidence of cytokine storm (CRS) was 33% (3 / 9), and all were grade 1 CRS. The risk of CRS was significantly lower than that of hematological malignancies treated with CD19CAR-T. None of the patients developed autoimmune diseases after treatment.
[0134] Therefore, the therapeutic approach of the present invention, which involves modifying cTIL cells using the expansion factor CD19CAR and the enhanced receptor and then infusing them into subjects, does not cause uncontrollable and serious side effects and has ideal safety.
[0135] 3.2 Evaluation of treatment effect Based on imaging examinations at baseline before infusion and two months after cell infusion, the results showed that all subjects had effective overall disease control within the six-week observation period after cell infusion. The disease control rate of ScTIL in this application for advanced solid tumors was approximately 100% (9 / 9), meaning that the patient response rate to treatment was 100%. Of these, three patients' tumors showed significant shrinkage or disappearance of activity, meaning that the objective remission rate was 33% (3 / 9).
[0136] [Table 2]
[0137] The RECIST criteria were used to evaluate the therapeutic effects in the rightmost column of Table 2. The radiological data for patients 1 to 4 are shown in Figure 16, with lesions indicated by arrows or rulers. As shown, the tumor lesions significantly shrank after treatment.
[0138] Therefore, the present invention provides an amplifier CD19CAR and an enhanced receptor-modified PD-1 + T cells can effectively control and even treat a variety of different solid tumors and have a wide spectrum of potential applications, so their effectiveness is not related to the patient's tumor gene mutation burden, and therefore their application is not limited to patients with high TMB.
[0139] 3.3 Accelerating validation of the in vivo amplification properties of CAR ScTILs At various time points after infusion (30 minutes, 24 hours, 4 days, 7 days, 10 days, 14 days, 28 days, 71 days, and 91 days), peripheral blood samples were collected for flow cytometry to detect the number of CAR-positive cells and the proportion of lymphocytes. The proportion of CAR-positive cells (i.e., ScTIL cells) in the peripheral blood of patients 1 and 2 was dynamically monitored, and the absolute number in the patient's body was calculated. The proportion of expanded ScTIL cells in the peripheral blood was calculated using the following formula:
[0140] Amplification factor = [lymphocyte concentration (cells / L) × circulating blood volume (L) × percentage of ScTILs among lymphocytes] / number of ScTILs transfused
[0141] The data show that the number of CAR copies in peripheral blood 30 minutes after cell infusion significantly exceeds the effective cell dose, indicating that rapid proliferation begins immediately after cell infusion. Therefore, the amount of infused cells can be directly used as the base number in the above calculation, and the peripheral blood CAR value detected by blood sampling 30 minutes after infusion cannot be used as a baseline value that has not already been amplified.
[0142] The lymphocyte count can be determined by standard blood tests, and the proportion of ScTILs among T cells can be determined by flow cytometry, which shows that CAR+ cells are CD3+. + The total circulating blood volume was calculated based on the kilogram body weight before cell infusion therapy, with the total blood volume (liters / L) calculated as 80 ml / kilogram body weight for men and 75 ml / kilogram body weight for women.
[0143] On day 14 (D14) after ScTIL infusion, patients 1 and 2 were randomly selected, and the amplification fold of ScTIL in peripheral blood was detected and calculated to be 140-fold and 754-fold, respectively. At the same time, the number of peripheral blood B cells was found to have significantly decreased to 8%-25% of the pre-infusion level (a 75%-92% decrease in number).
[0144] [Table 3]
[0145] Even though the patients were not administered exogenous immunoglobulin during the observation period, none of the patients developed immunodeficiency.
[0146] Therefore, the cTIL cells modified with the expansion factor CD19 CAR in the present invention can effectively support their expansion in vivo through the recognition of B cells by the CD19 CAR.
[0147] 3.4 Verification of ScTIL dual identity The ScTILs of the present invention are derived from peripheral blood-derived TILs (cTILs), and these T cells have the ability to naturally recognize tumors, i.e., the primary recognition ability of T cells. Furthermore, by introducing a CD19 CAR design that targets B cells based on ScTILs, ScTILs can be significantly expanded in vivo by stimulating B cells against their target CD19.
[0148] Patients 1 and 2 (Tables 1 and 2) were randomly selected and their peripheral blood circulating tumor cell counts (CTCs) were dynamically monitored, comparing the baseline values on the day of infusion with the retest values within 2 months after infusion. The results showed that both subjects had a significant decrease in the number of CTCs per 5 milliliters of peripheral blood 2 months after infusion of ScTIL cells, as shown in the table below.
[0149] [Table 4]
[0150] Therefore, the cTIL cells carrying the expander CD19 CAR of the present invention can not only recognize B cells via the CD19 CAR to induce large-scale expansion of TILs or tumor-distinguishing T cells in the body, but also recognize and kill tumor cells in tumor patients through their own natural recognition properties against tumor cells. Such dual recognition ability of the modified immune cells of the present invention has been successfully demonstrated in the above-mentioned clinical trials.
[0151] 4. Evidence and analysis of treatment effects Although the disease control rate of ScTIL therapy in this example was 100%, the infusion of natural TIL cells alone is insufficient to achieve such a therapeutic effect, for the following reasons.
[0152] 1) The number of cells infused was insufficient to produce such a therapeutic effect. The number of T cells detected in peripheral blood after expansion (10 5 ~10 6 Based on this dose (100 mg / kg body weight), and taking into consideration previous literature reports on cell therapy (for example, in Steven Rosenberg's report on neoantigen-reactive T cell or TIL therapy, the amount of cells infused was approximately 10 to the power of 11), this dose is lower than the usual infusion dose and is therefore insufficient to achieve the therapeutic effect observed in this example when treating solid tumors. 2) The origin of ScTILs is TILs, which are usually exhausted T cells. Without genetic modification, the tumor-killing activity of TILs is very limited, and thus the infusion of such low doses of exhausted T cells is insufficient to achieve the therapeutic effect in this example. Therefore, based on the therapeutic effect data of this example, in the present invention, the enhanced receptor is PD-1 + This provides indirect evidence that applying this technology to T cells can enhance the tumor-suppressing ability of these peripheral blood-derived immune cells.
[0153] 5. Summary Taking into account the multiple experimental results in this example, it can be summarized that the ScTIL therapy of the present invention has the following characteristics.
[0154] 1) PD-1 can be isolated from readily available peripheral blood through simple selection. + Since T cells (cTIL) can be obtained, tumor-distinguishing T cells can be obtained quickly, shortening the preparation cycle. 2) The enhanced receptor is designed to enhance tumor-killing efficiency by converting super cTIL (ScTIL) cells from a suppressed to an activated state. 3) The design of the CAR targeting B cells (CD19) allows for significant expansion of ScTIL cells in vivo, so only a very small amount of ScTIL cells needs to be prepared and there is no need to expand them in large quantities in vitro. 4) The cell preparation process is simple and rapid, and does not require the complicated steps of gene sequencing, screening, synthesis, etc. that are required in conventional new antigen therapy technologies, which significantly shortens the preparation period and reduces the preparation costs. 5) The ScTIL therapy of the present invention has shown very good therapeutic effects in patients with different cancer types and solid tumors for which conventional multi-line therapy has not been effective, and has potential and wide-ranging application aspects. 6) Our ScTIL therapy has an ideal safety profile, including a) no toxic side effects such as severe off-target or autoimmune diseases; b) only a mild cytokine storm (CRS) is observed, which is significantly lower than the CRS level observed in CAR-T-based treatment of B-cell hematologic malignancies; and c) normal B cells are killed, but the side effects are less severe than those observed in CAR-T-based treatment of B-cell hematologic malignancies. This is because, after treatment of B-lineage hematologic malignancies with CD19 CAR-T, B-cell deficiency typically persists for 18 months or more, and some patients require lifelong replacement immunoglobulin therapy. In contrast, after treatment with ScTIL, all B cells recovered within 1–3 months and stabilized at levels approaching or reaching the lower limit of the normal physiological range, and immunoglobulins in all subjects remained below the lower limit of the normal physiological range during this period.
[0155] Example 6. Elimination of residual virus from associated pre-existing HBV infection In a clinical trial using ScTIL cells to treat patients with solid tumors, the inventors surprisingly observed that abnormalities appeared in hepatitis B markers and liver enzymes in patients after treatment with the modified immune cells (ScTIL) of the present invention. Based on these observations, the inventors speculated and designed experiments to verify the results, and then proposed that the immune cells of the present invention can be used to treat diseases related to HBV infection and to treat HBV virus remaining in the body.
[0156] 1. Abnormalities in hepatitis B markers and liver enzymes after ScTIL cell therapy: Nature and causes In clinical trials, the following phenomena were observed in two out-group patients after treatment with ScTIL cells:
[0157] Liver function and HBV markers detected at baseline were normal, and the following appeared after cell therapy: 1) ALT / AST were above the upper limit of the normal range. 2) HBsAg was transiently positive, and HBsAb and / or other antibodies subsequently became positive, but HBV DNA copy number and HBcAb IgM consistently remained negative. 3) The subjects did not have subjective clinical features of acute hepatitis (such as anorexia, jaundice, hepatomegaly, and hepatomegaly with tenderness). 4) The cell product used for transfusion was negative for HBV detection, and plasma immunoglobulins maintained normal physiological levels.
[0158] In order to determine the causes of the above phenomena, a multi-parameter experiment was designed and carried out to answer the following questions and analyze the triggers that cause these phenomena.
[0159] 1) Is there contamination of cell products with HBV or exogenous HBV infection?
[0160] The presence of HBV in the cell product and in the subjects' peripheral blood was detected, and both results were negative. Therefore, it can be confirmed that the cell product was not contaminated with HBV and that the subjects did not develop exogenous HBV infection during the clinical trial.
[0161] 2) Did the decrease in immunoglobulins secondary to the decrease in B cells increase susceptibility to the HBV virus, leading to secondary infection?
[0162] Although we observed that the peripheral blood lymphocyte count decreased compared to the pretreatment baseline level after patients received ScTIL cell therapy, this possibility can be excluded because plasma immunoglobulin concentrations were always maintained within the normal physiological range.
[0163] 3) Are the liver dysfunction abnormalities due to adverse effects related to cell therapy or autoimmune liver injury?
[0164] This possibility can be ruled out because ScTILs are not chemically toxic and their molecular mechanism of action can ensure that they do not damage autologous healthy tissues.
[0165] 2. Basic condition of the patient Case 1 (WJ) A 36-year-old woman with gastric signet ring cell carcinoma and cervical metastasis had been diagnosed for 2 years. Sequencing revealed TMB 1.03, novel antigen 16, and full HLA heterozygosity. Mononuclear cell apheresis was performed on November 15, 2019, and the total number of cells collected was 5.5 x 10E9 / 62 ml. The ScTIL cells used in this example were essentially the same as those in Example 5, except that the V2E-enhanced receptor (SEQ ID NO: 2) was used instead of the V1E-enhanced receptor, and the TIL cells were transfected with CD19-CAR to obtain ScTILs. Therapeutic cell preparation: 2 bags of 70 ml ScTIL cells + 1 bag of 30 ml ScTIL cells, total effective cell count 2.5 x 10E9. The cells were infused in two infusions, on December 13, 2019 (70ml, effective cell count 1.03x10E9) and December 18, 2019 (70+30ml, effective cell count 1.47x10E9), and both infusions went smoothly. Six hours after completion of both infusions, the patient developed a rise in body temperature, complained of chills, headache, and mild nausea, but did not experience vomiting or other particular discomfort. The fever persisted for three days and then subsided to normal levels.
[0166] Hepatitis B-related indicator detection status: 1) Tests performed on November 18, 2019 (before treatment) and December 16, 2019 (the day of the first cell infusion) showed no abnormalities in the liver enzyme spectrum or the five hepatitis B parameters. 2) A re-examination 21 days after the second infusion (2020 / 01 / 09) revealed normal liver enzyme spectra. 3) Re-examination 64 days after the second transfusion (2020 / 02 / 20) revealed an increase in the liver enzyme spectrum, with ALT 65U / L (normal range 0-50UL) and AST 61U / L (normal range 0-40U / L), and the five hepatitis B items were not tested at that time. 4) Retesting 115 days after the second transfusion (April 15, 2020) revealed that liver function enzyme levels had fallen to the normal range, but the five hepatitis B parameters were positive for hepatitis B surface antibodies and core antibodies (retesting the following day was negative), but the HBV DNA copy number test result was negative.To rule out HBV contamination of the cell product, the "apherase sample for cell preparation" and "finished cell sample" were sent to a third-party testing agency on the same day, and all hepatitis B virus test results were negative.
[0167] During the time period when the above liver enzyme and five hepatitis B abnormalities were observed, the patient complained of mild anorexia, but did not experience nausea, vomiting, swelling, or pain in the liver region, nor did he develop symptoms commonly associated with acute infectious infections such as hepatomegaly or jaundice. The patient's liver function and HBV-related indicators are shown in Figure 8A.
[0168] Case 2 (SSY) A 46-year-old male with sigmoid colon cancer and perigastrointestinal lymph node metastasis. Sequencing revealed TMB 2.3, novel antigen 7, and HLA pan-heterozygosity. On November 15, 2019, mononuclear cell apheresis was performed, yielding a total cell count of 4.66 x 10E9 / 54 ml (1.8 x 10E9 remaining cells after preparation). Treatment cell preparation consisted of two 50 ml bags of ScTIL cells, with a total effective cell count of 9.91 x 10E8. Cells were infused in two infusions, on January 2, 2020, and January 6, 2020, with a total volume of 4.955 x 10E8 / 50 ml, and the process was uneventful. Seven hours after the first infusion, chills appeared, and the body temperature rose to a maximum of 39.6°C. After oral administration of antihistamines and physical cooling, the temperature returned to normal. The fever lasted for 3 days, with no other symptoms except weakness, and the temperature then naturally decreased to normal levels. No obvious temperature changes or discomfort were observed after the second infusion.
[0169] Hepatitis B-related indicator detection information: 1) The patient underwent three tests on December 9, 2019 (before treatment), January 6, 2020 (the day of the second cell infusion), and January 16, 2020 (10 days after the second cell infusion), all of which showed no abnormalities in the liver enzyme spectrum, and the five hepatitis B test results before treatment were negative. 2) Re-examination 77 days after the second transfusion (March 23, 2020) revealed elevated liver enzymes, with ALT 163U / L (normal range 0-50UL) and AST 113U / L (normal range 0-40U / L). Five hepatitis B tests were not performed at that time. 3) In a re-examination 85 days after the second transfusion (April 1, 2020), ALT was 743U / L (normal range 0-50U / L), AST was 243U / L (normal range 0-40U / L), and the five hepatitis B parameters were positive for hepatitis B surface antigen and core antibody, but negative for core antibody IgM. 4) In a re-examination 93 days after the second transfusion (April 9, 2020), ALT was 301U / L (normal range 0-50U / L), AST was 76U / L (normal range 0-40U / L), and the five hepatitis B parameters showed that hepatitis B surface antigen had become negative, but core antibody remained positive. 5) When retested 132 days after the second infusion (April 9, 2020), both ALT and AST levels had decreased to the normal range, and the five hepatitis B tests were not performed.
[0170] During the time period when the above liver enzyme and five hepatitis B abnormalities were observed, the patient complained of mild anorexia, but did not experience nausea, vomiting, swelling or pain in the liver region, or any other symptoms commonly seen in acute infectious infections such as hepatomegaly or jaundice. The patient's liver function and HBV-related indicators are shown in Figure 8B.
[0171] Control cases - true HBV infection (CY) A 26-year-old woman with multiple lung metastases after colon cancer surgery received ScTIL cell infusion therapy (effective cell dose 6.4 × 10E8) on May 9, 2019. Hepatitis B markers were detected on August 1, 2019, with negative results. However, on September 13, 2019, a case of suspected hematogenous HBV exposure was identified. On October 12, 2019, hepatitis B surface antigen and e antigen were positive, antibodies were negative, and hepatitis B virus DNA copy number was positive. After hepatoprotective therapy, retesting on November 12, 2019 showed that hepatitis B antigen and hepatitis B virus DNA copy number both returned to negative, while hepatitis B surface antibody and core antibody returned to positive. The patient's liver function and HBV-related indicators are shown in Figure 8C.
[0172] 3. Mechanism of correlation between hepatitis B markers, liver enzyme abnormalities, and cell therapy The two patients described above were characterized by the following: While observing the antitumor therapeutic effects of immune cells, elevated liver enzymes (ALT, AST) were detected 6 to 8 weeks after cell infusion; HBsAg (surface antigen) became transiently positive (reverting to negative after 1 week); HBsAb / HBcAb (surface antibody / core antibody) subsequently changed from negative to positive; and liver enzymes decreased to normal levels. During this period, peripheral blood tests for hepatitis B virus (HBV) DNA copy number and HBcAb IgM in the cell product were negative; plasma immunoglobulins (IgG, IgM, IgA) were all within the normal range.
[0173] The inventors believe that this phenomenon is related to the presence of small amounts of viral components in hepatocytes after conventional HBV infection (Figure 9), and the suppression of the viral DNA replication / assembly / exocytosis program by the host's enhanced immune function. After HBV infection, HBV proteins presented on the hepatocyte MHC mechanism can be recognized by immune lymphocytes, but the immune lymphocytes' attack on target cells is suppressed by the immune killing escape mechanism of virus-infected hepatocytes (PD-L1 expression on hepatocytes), thereby preventing immune destruction of hepatocytes containing HBV components and elimination of HBV (Figure 10). This significantly weakened immune function also increases the risk of recurrence of hepatitis B infection.
[0174] In the examples of this application, mononuclear cells used for collection and preparation of ScTILs were selected using PD-1 antibody magnetic beads and were PD-1 positive (PD-1 + ) lymphocytes. As described above, these PD-1 +These cells contain a subset of CTLs that specifically recognize HBV-displayed membrane proteins but whose killing activity against target cells is inhibited by PD-L1 expressed by hepatocytes. These cells were transfected via lentivirus to carry enhanced receptors, reactivating their cell-killing ability. After reinfusion, these modified cells (ScTILs) recognize target cells expressing HBV proteins via their specific TCR and interact with highly expressed PD-L1 on target cells via the extracellular domain of the membrane-enhancing factor PD-1, thereby inducing further activation of ScTILs and enhanced killing of target cells. Hepatocytes destroyed by CTL attack release HBV components into the peripheral bloodstream and induce humoral immunity and increased antibody titers, manifested as transient HBsAg positivity and secondary antibody positivity (Figure 11). During previous hepatitis B virus infection, active viral particles already assembled within host cells are not affected by the inhibition of viral replication by interferon, and are released into the blood via an active exocytosis mechanism without remaining within host cells. Therefore, active HBV viral particles are released into the blood upon hepatocyte destruction, and dissemination of infection does not occur. This assumption is supported by HBV DNA and HBcAb IgM negative detection results.
[0175] In summary, based on the experimental results, the inventors speculate that ScTIL, as a combination of heterogeneous T lymphocyte subsets with specific antigen recognition ability, exerts an anti-malignant solid tumor effect while simultaneously eliminating the potential risk of recurrence of past viral infections in the future when immunity is weakened by removing viral components that potentially remain in some target cells after previous infection.
[0176] Therefore, the modified immune cells of the present invention can treat tumor diseases in tumor patients while simultaneously eliminating viruses in the body and preventing the recurrence of virus-related diseases.
[0177] 4.Applications Based on the findings in the above experiments and the clinical implications of pseudo-HBV infection that appeared after ScTIL cell therapy, the following scenarios and applications for ScTIL cell therapy of the present invention are proposed.
[0178] 4.1 Differential diagnosis between pseudo-HBV infection and true HBV infection (see control cases) after cell therapy Characteristics of pseudo-HBV infection after ScTIL cell therapy: (1) The HBV DNA copy number was below the threshold for positivity. (2) Abnormalities in liver enzyme spectrum and HBV antigen appeared first and persisted for 1-2 months before recovering to normal. (3) HBV antibodies appeared relatively late and remained positive for a long period of time.
[0179] True HBV infection is characterized by: (1) The HBV DNA copy number was elevated, the antigen was positive, and the titer was high. (2) Liver enzyme abnormalities usually show a positive correlation with quantitative abnormalities of HBV antigen.
[0180] 4.2 Elimination of residual HBV viral components using ScTIL therapy After a previous HBV infection has been cured, HBV components that are in the process of replicating remain in some liver cells, and this can cause recurrence of infection when the body's immune system is weakened.
[0181] A specific subset of peripheral blood PD-1-positive lymphocytes specifically recognizes and expresses HBV membrane protein components displayed on the hepatocyte membrane, but because this expression is suppressed by secondary PD-L1 expression, it is unable to kill target cells for residual viral components.
[0182] The enhanced receptor molecules of ScTIL can overcome the immune escape induced by PD-L1, eradicating residual HBV viral components in the body and eliminating the risk of future recurrence of infection.
[0183] Example 7. PD-1 modified with enhanced receptors + Treatment of diseases associated with HPV virus infection with T cells Using the method described in Example 5, PD-1 was detected in peripheral blood samples from patients with HPV-positive tumors. + T cells were selected and ScTIL cells expressing the enhanced receptor and optional CD19 CAR were prepared, which were then infused into patients to treat tumors and clear HPV infection.
Claims
1. A modified immune cell, the immune cell being a peripheral blood-derived PD-1 positive T (PD-1 + The modified immune cells are T) cells.
2. The PD-1 + The modified immune cell of claim 1, wherein the T cell is derived from a peripheral blood mononuclear cell (PBMC).
3. The modified immune cell of claim 1 or 2, wherein the modification comprises genetic modification or cell surface protein modification.
4. The modification is + The modified immune cell of claim 3, which results in the deletion or reduction of PD-1 expression or inhibition of PD-1 function in T cells.
5. The modified immune cell of claim 4, wherein the deletion or reduction of PD-1 expression is achieved by knocking out or down the PD-1 gene.
6. 5. The modified immune cell of claim 4, wherein the inhibition of PD-1 function is achieved by contacting the immune cell with a PD-1 antibody in vivo or in vitro, wherein the contact causes the PD-1 antibody to bind to PD-1 on the surface of the immune cell.
7. 7. The modified immune cell of any one of claims 1 to 6, wherein the modified immune cell comprises an enhanced receptor (ER) comprising an extracellular domain (ECD) and an intracellular domain (ICD), the ECD capable of binding to a target cell of the immune cell, and the ICD comprises a costimulatory molecule or a fragment thereof that induces an immune cell activation signal.
8. The modified immune cell of claim 7, wherein the ECD comprises a receptor, ligand and antibody for a membrane protein of the target cell, or a portion or fragment of a receptor, ligand and antibody for a membrane protein of the target cell, which portion or fragment has the function of binding to the target cell.
9. The modified immune cell of claim 8, wherein the ECD comprises a partial sequence of PD1 or an anti-PD-L1 antibody, preferably an anti-PD-L1 scFv, and / or the ICD is derived from CD28.
10. The modified immune cell according to any one of claims 1 to 9, which has the ability to target a target cell in a subject.
11. The modified immune cell of claim 10, wherein the target cell is one or more selected from the group consisting of a tumor cell, a cancer cell, and a virus-infected cell.
12. The modified immune cell according to claim 11, wherein the virus is a hepatitis virus, preferably a hepatitis B virus, or a human papilloma virus.
13. The modified immune cell according to any one of claims 1 to 12, further expressing a chimeric antigen receptor (CAR), said CAR specifically recognising another antigen, preferably CD19, which is an antigen different from the antigen recognised by the native TCR of said immune cell.
14. The modified immune cell of any one of claims 1 to 13, further comprising other modifications that control immune cell death, such as a death switch.
15. A cell population comprising the modified immune cell according to any one of claims 1 to 14.
16. 1. A method for preparing therapeutic immune cells, the method comprising: (a) PD-1 from peripheral blood + selecting T cells from the (b) PD-1 selected in the step (a) + T cells were treated with the following: i. knocking out or down expression of PD-1; ii. Mix with PD-1 antibody; iii. Expressing Enhancer Receptor (ER); iv. Expressing a chimeric antigen receptor (CAR); v. expressing the death switch; and 2. A method for preparing therapeutic immune cells comprising:
17. A modified immune cell obtained by the method of claim 16.
18. A composition comprising an immune cell according to any one of claims 1 to 14 or 17 or a cell population according to claim 15.
19. (1) treatment of tumors, and / or (2) Treatment or prevention of a disease or symptom associated with a viral infection, or prevention of the recurrence of a disease or symptom associated with a viral infection.
20. The composition of claim 18 for use in
